Entera Bio's (ENTX) Buy Rating Reaffirmed at HC Wainwright

Entera Bio (NASDAQ:ENTX - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright's target price would suggest a potential upside of 412.82% from the stock's previous close.

Entera Bio Stock Up 1.0 %

Shares of Entera Bio stock traded up $0.02 during trading hours on Tuesday, reaching $1.95. 19,531 shares of the company's stock were exchanged, compared to its average volume of 113,376. Entera Bio has a 1 year low of $1.41 and a 1 year high of $3.35. The company has a market capitalization of $69.78 million, a P/E ratio of -7.50 and a beta of 1.62. The business has a fifty day moving average of $2.18 and a two-hundred day moving average of $2.02.

Hedge Funds Weigh In On Entera Bio

A number of institutional investors have recently bought and sold shares of ENTX. Parkman Healthcare Partners LLC increased its holdings in shares of Entera Bio by 2.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company's stock worth $781,000 after buying an additional 9,558 shares during the last quarter. Perigon Wealth Management LLC purchased a new stake in shares of Entera Bio during the 4th quarter valued at approximately $325,000. Northern Trust Corp purchased a new stake in shares of Entera Bio during the 4th quarter valued at approximately $450,000. Finally, Knoll Capital Management LLC raised its position in shares of Entera Bio by 51.5% during the 4th quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company's stock valued at $12,470,000 after buying an additional 2,000,000 shares during the period. 14.11% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.